Novartis’ Cosentyx Gains EU Approval for New Indication

The European Commission has approved Novartis’ Cosentyx (secukinumab) for adults with active non-radiographic axial spondyloarthritis.

The approval was based on results of a phase 3 trial in which 41.5 percent of patients showed a significant and clinically meaningful reduction in disease activity vs. a placebo.

Cosentyx was originally approved in 2015 as a first-line treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.